Life sciences teams rarely face FDA action because Veeva or Workday can't technically meet requirements. The real risk comes when a former employee's account remains active, tied to regulated records months after departure.

This guide details, step by step, how to:

  • Link orphaned Veeva (and related) accounts to 21 CFR Part 11 risk
  • Build joiner-mover-leaver (JML) controls that actually mitigate those risks
  • Use identity governance (IGA) to automate deprovisioning and audit evidence
  • Turn 2026 regulatory requirements into a sustained advantage, not a fire drill

The focus is biotech and pharma teams running Veeva alongside other GxP and business applications-with lean IT and active FDA oversight.

Why orphaned Veeva accounts are now an FDA issue-not just an IT problem

Title 21 CFR Part 11, finalized in 1997, sets FDA requirements for electronic records and signatures used to satisfy predicate rule obligations1en.wikipedia.org.

For any closed system (Veeva Vault, CRM, QMS, LIMS, ELN, etc.), Part 11 requires you to:

  • Control record creation, modification, and approval
  • Maintain tamper-evident, time-stamped audit trails
  • Retain those audit trails as long as the underlying records and make them available to inspectors

Section 11.10(e) of 21 CFR Part 11 mandates secure, computer-generated, time-stamped audit trails for actions that create, modify, or delete electronic records. Those trails must preserve previous entries and be available for FDA inspection for at least the record lifecycle2fda.gov.

FDA's recent guidance for electronic systems and clinical investigations reinforces that audit trails and traceability-including who took what action, when, and why-are non-negotiableFDA's 2023-2024 guidance on electronic systems emphasizes retention and availability of audit trail documentation for FDA review2fda.gov.

Why does this matter for orphaned accounts?

  • An orphaned Veeva account (active post-termination or without an HR record) can still access systems controlling batch records, submissions, or quality events.
  • Activities from such accounts appear in audit trails as legitimate actions by current personnel.
  • During inspections, you can't prove only authorized, trained staff conducted those actions.

Recent FDA data-integrity warning letters frequently cite weak authentication and shared or uncontrolled accounts as violations of 21 CFR Part 11 and GMP3certivo.io.

This is playing out in the field:

Life sciences access vendors warn that former employees retaining access to LIMS, eQMS, and batch systems create data-integrity risks and critical violations during inspections4amplelogic.com.

With 2026 bringing DORA, NIS2, CMMC 2.0, and a shift to live evidence, manual offboarding and SSO-only controls are regulatory liabilities, not just IT challenges5bakertilly.de.

The good news: You don't need a lengthy SailPoint deployment. With solid JML design and an IGA platform that covers Veeva, Workday, and your stack, you can address this now.

What you need before you start

Full maturity isn't mandatory, but you need a few core foundations:

  • Authoritative people source
    HRIS (often Workday) or a governed HR database tracking joiners, movers, and leavers.

  • Central identity provider (IdP)
    Okta, Entra ID, or equivalent, even if not all apps are behind SSO yet.

  • List of regulated systems and records
    Veeva apps (Quality, RIM, Clinical, PromoMats), Veeva CRM, LIMS/ELN, QMS, MES, EDC, and any system storing Part 11 records.

  • Cross-functional support
    Representatives from IT/Infrastructure, QA/Quality Systems, and Compliance/Regulatory empowered to decide.

  • An IGA strategy
    Either you're already running identity governance, or 2026 is when you move beyond ticket-driven access. Iden is purpose-built for lean teams needing modern IGA without legacy complexity.

Step 1: Map where 21 CFR Part 11 applies in your stack

Before tracing orphaned accounts, define your regulatory scope.

  1. List all electronic records fulfilling FDA rules. Typical examples:

    • Electronic batch records
    • Deviation, CAPA, change-control records
    • Training records
    • Validation/CSV documentation
    • Study data, eCRFs/eCOA
    • eTMF, submission documents

  2. Map records to systems. For each Veeva app and related tool, note which records are Part 11-relevant.

  3. Identify who can access or alter these records. For every system:

    • Who can create/modify/approve?
    • Who can alter workflows/security?
    • Who can manage user accounts?

  4. Deliberately exclude out-of-scope systems. Not every SaaS app is Part 11-relevant. Be explicit; risk-based reasoning meets inspector expectations.

Tip
Document your mapping once and use it for CSV/CSA, risk assessments, and training matrices. It will also support access reviews later.

Step 2: Define "orphaned" and "risky" accounts for your environment

Orphaned accounts aren't just former employees with active logins. Any account breaking attribution to a real, authorized individual jeopardizes Part 11 compliance.

Set definitions upfront:

  • Orphaned accounts
    • No active HR/contractor record
    • Marked as terminated in HR but active in Veeva or other apps
    • Active in some systems, disabled in others
  • Shared or generic accounts
    • Accounts like "labuser1" or "qa_approver" used by multiple people
    • Human use of service accounts
  • Privilege-creep accounts
    • Roles no longer match job function (e.g., ex-QA lead with lingering approval rights)

Current Part 11 guidance and GxP data-integrity best practices stress unique user IDs, avoidance of shared logins, and strong access controls and audit trails6yaveon.com.

Document these definitions with IT and QA sign-off. They'll drive your IGA automation policies.

Common mistake
Treating only "terminated but still active" as orphaned. Shared accounts (like "lab1") break traceability just as severely.

Step 3: Baseline your current state in Veeva, Workday, and key GxP apps

Take a cross-system view of your starting point.

3.1. Export a full Veeva user inventory

If using Veeva Vault:

  1. Export active users and roles via Vault Admin.
  2. Include metadata (last login, role, org/site).
  3. Repeat for each Vault domain you run.

Veeva supports robust controls, but places account management squarely with the customer:

Veeva's 21 CFR Part 11 compliance assessment: Vault provides audit trails and access controls, while admins are responsible for configuring accounts, roles, and privileges to meet regulatory demands7sites.veevavault.help.

3.2. Reconcile against HR (Workday) and IdP

  1. Export all active workers/contractors from Workday or HRIS.
  2. Export enabled identities from IdP (Okta/Entra ID), including department, manager, and status.
  3. Match Veeva accounts to HR + IdP via email, employee ID, or another key.

Flag discrepancies:

  • Veeva users missing in HR/IdP
  • Terminated workers with active Veeva/GxP accounts
  • Dormant accounts holding high-risk permissions

3.3. Reconcile across LIMS, ELN, QMS, MES, EDC

Repeat reconciliation for each regulated app, prioritizing your top five by risk.

Tip
A full IGA platform, like Iden, facilitates pulling user and entitlement data from any app (SCIM, API, or neither) and aligning that with HR and IdP. Stop juggling spreadsheets-start automating.

Step 4: Design JML flows that default to closing orphaned accounts

Now design how access should flow.

4.1. Standardize your triggers

For each identity type (employee, contractor, partner):

  • Joiner: HR status set to hired/ready
  • Mover: Changes to department, role, cost center, or manager
  • Leaver: HR status to terminated or contract expired

Map each trigger to required actions in Veeva and other Part 11 systems:

  • Which accounts to create or disable
  • Roles/groups to assign or remove
  • Training/qualification checks before access

4.2. Build JML automation into IGA-not tickets

Manual tickets and checklists don't scale or supply strong evidence. Regulators in 2026 demand automated, traceable controls.

Modern Part 11 compliance expects proactive audit trail review, continuous monitoring, and integration with IAM, MFA, and automated-not procedural-controls8mavenrs.com.

An Iden-enabled setup typically runs as follows:

  • HR/Workday drives employment status as the ultimate source.
  • IdP (Okta/Entra) plus Iden define standard Veeva and GxP access per role.
  • When HR marks someone as terminated, Iden automatically:
    • Disables or revokes accounts in all scoped apps
    • Logs all deprovisioning events
    • Optionally triggers QA review for high-risk roles

Iden customers see up to 80% fewer manual tickets and save about 120 hours per quarter on user access reviews when JML and review workflows are automated.

Common mistake
Relying solely on "disable in Okta." Users may still access systems with local credentials or API keys-especially in legacy or partly integrated environments. Inspectors won't buy that story.

Step 5: Clean up user account hygiene in Veeva and regulated apps

Automation alone isn't enough-ensure accounts themselves align to Part 11 standards.

5.1. Enforce unique, attributable accounts

Part 11 and data-integrity guides call for individually traceable logins. Shared or generic accounts are leading causes of compliance findings6yaveon.com.

What to do:

  • Eliminate shared accounts. Where justified for legacy cases, document tightly and control access rigorously.
  • Ensure Veeva user IDs are uniquely mapped to HR identities.
  • Restrict account creation to IGA, not manual entry.

5.2. Right-size roles and privileges

  • Match Veeva roles (editor, approver, admin) to HR job functions.
  • Use Iden for fine-grained entitlements: beyond app access, down to Vault role, study team, or business unit where needed.
  • "Mover" automation ensures promotions or transfers update all system roles.

5.3. Ensure audit trails are complete and usable

Veeva delivers strong native audit logging:

Veeva Vault's Part 11 assessment: audit trail records user entries and all record actions for creation, modification, or deletion, and logs are available for review and download7sites.veevavault.help.

Leverage this, but verify:

  • Audit trail logging enabled for all relevant objects and workflows
  • Filtering by user, record, date, and action supported
  • Audit logs included in archiving/backups for full retention period

Iden layers on cross-system audit evidence:

  • Every provisioning or deprovisioning generates an independent record
  • Auditors can see both "who did what in Veeva" and "how and why that access was assigned"

Tip
During mock audits, practice tracing a batch or submission from "who created/approved in Veeva?" back to "how did they get that access, and was it reviewed?" With Iden, all evidence is unified and readily available.

Step 6: Automate access reviews and evidence generation

Access reviews move teams from "compliant on paper" to "truly audit-ready."

6.1. Set review scope and cadence

For Veeva and other regulated systems, base cadence on risk and QA:

  • Quarterly reviews: high-risk roles (approvers, admins)
  • Semiannual/annual: read-only users
  • Triggered reviews: business changes (acquisitions, closures)

Part 11 audit and compliance guidance expects regular, structured reviews with automated monitoring-not just manual spot checks9simplerqms.com.

6.2. Move from spreadsheets to automated IGA campaigns

With Iden, you can:

  • Launch review campaigns (e.g., Quarterly Veeva Vault Quality Access Review)
  • Route entitlements to managers or QA for approval
  • Supply business context (role, activity, last login)
  • Auto-revoke non-certified access
  • Capture complete audit trails of reviews and decisions

This approach meets evolving inspector demands: "Show me live access control evidence" rather than just procedures.

Common mistake
Treating access reviews as an annual GRC exercise. For Part 11 systems, it must be a continuous, jointly owned IT/QA control.

Step 7: Extend beyond Veeva-close SSO blind spots

Veeva is only part of your regulated environment.

  • Workday holds employment and training status
  • LIMS/ELN/MES manage lab/manufacturing data
  • QMS covers deviations, CAPAs, and change control
  • EDC/eCOA store clinical data

Part 11 and integrity rules apply wherever regulated records live.

Regulatory and industry guidance requires 21 CFR Part 11 controls for all electronic records supporting GMP, GLP, or GCP, across on-prem, cloud, and any vendor6yaveon.com.

Many systems:

  • Lack SCIM support
  • Are outside your IdP
  • Still rely on manual provisioning

Iden is built to close this gap:

  • Universal connectors enable governance over any app-SCIM, API, or none-integrating Veeva, Workday, and even legacy LIMS
  • Fine-grained controls manage access at study, site, or product-line levels-not merely app-level
  • No SCIM-tax means you can automate even without enterprise vendor upgrades

Tip
Inventory "shadow GxP" systems-shared drives, instrument PC software, etc. These often harbor the riskiest orphaned accounts and weakest trails.

Next steps: Move from patchwork to a defensible IGA program

By following these steps, you will:

  • Define and document orphaned/risky accounts
  • Know exactly where those accounts exist across Veeva and beyond
  • Build JML and access review controls to keep them from returning
  • Show auditors live, cross-system evidence of access control

Typical next moves for biotech and pharma teams:

  1. One-time cleanup via your inventory.
    Resolve all orphaned accounts in Veeva, Workday, LIMS, ELN, QMS, and EDC.
  2. Implement Iden as your IGA layer.
    Integrate HR, IdP, Veeva, then expand to other regulated apps. Iden connects to any app and goes live in a day-so you make real progress this quarter.
  3. Automate your access policies.
    Encode Part 11 rules-who can do what, when, based on training/role-directly in Iden workflows.
  4. Update SOPs to match automation.
    Align procedures with your actual (automated) process, not the theoretical manual one.
  5. Use 2026 as your opportunity.
    As others scramble to retrofit for audits (FDA, DORA, NIS2, CMMC), you can demonstrate:
    • No orphaned accounts in Veeva and GxP systems
    • Fully attributable, up-to-date audit trails
    • Automated, closed-loop access review capability

FAQ

How do orphaned Veeva accounts threaten 21 CFR Part 11 compliance?

Part 11 compliance relies on knowing who did what, when, and under whose authority. If terminated or shared accounts are active, you can't prove only authorized, qualified individuals acted on regulated records. That undermines the audit trail and your quality system in any inspection.

Isn't Veeva "Part 11 compliant" by default?

Veeva delivers the technical controls-secure audit trails, role-based access, and clear documentation7sites.veevavault.help. Regulators, however, focus on how you operate:

  • Are accounts mapped to individuals?
  • Are leaver accounts promptly disabled across all Vaults?
  • Do your access rules and reviews reflect your stated procedures?

That's your responsibility-Iden bridges the gap between "compliant in theory" and "compliant in daily operations."

Can we just disable users in Okta or Entra ID?

Only if every path to Veeva and GxP apps solely depends on IdP and there are no local logins, cached credentials, or admin backdoors. In reality, most organizations have a hybrid landscape. Iden's role: orchestrate deprovisioning across all apps, not only those linked to your IdP.

How often should we review access for Veeva and Part 11 systems?

Most organizations review high-risk roles quarterly (approvers, admins), and all users semiannually or annually. FDA expects the cadence to be risk-based, consistent, and result in actionable adjustments. Iden's automated reviews make this realistic for lean teams.

Is IGA overkill for a 200-person biotech?

Not today. You're running critical tools (Veeva, Workday, lab systems) with limited IT and genuine regulatory pressure. Lightweight, comprehensive IGA-Iden's specialty-gives you:

  • Automated offboarding and right-sizing across all apps, even those without SCIM
  • Continuous, audit-ready evidence for FDA, SOC 2, ISO 27001, and more
  • Fewer tickets and late-night access emergencies

With 2026 enforcement rewarding live, evidence-based controls, it's not overkill-it's a competitive advantage.

Book a call